Читать книгу Current Concepts in Movement Disorder Management - Группа авторов - Страница 75

1Munhoz RP, Werneck LC, Teive HA: The differential diagnoses of parkinsonism: findings from a cohort of 1,528 patients and a 10 years comparison in tertiary movement disorders clinics. Clin Neurol Neurosurg 2010;112:431–435.

2Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C: The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26(suppl 3):S2–S41.

3Connolly BS, Lang AE: Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311:1670–1683.

4Giugni JC, Okun MS: Treatment of advanced Parkinson’s disease. Curr Opin Neurol 2014;27:450–460.

5Pahwa R, Lyons KE: Treatment of early Parkinson’s disease. Curr Opin Neurol 2014;27:442–449.

6Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C: The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26(suppl 3):S42–S80.

7Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schüpbach M, Tolosa E, Trenkwalder C, Schapira A, Berardelli A, Oertel WH: Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol 2013;20:5–15.

8Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology: Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983–995.

9Munhoz RP, Teive HA, Eleftherohorinou H, Coin LJ, Lees AJ, Silveira-Moriyama L: Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2013;84:883–887.

10Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators: A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268–1278.

11Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G: The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 2014;137:2731–2742.

12Fox SH, Lang AE. ‘Don’t delay, start today’: delaying levodopa does not delay motor complications. Brain 2014;137(pt 10):2628–2630.

13Picillo M, Rocco M, Barone P: Dopamine receptor agonists and depression in Parkinson’s disease. Parkinsonism Relat Disord 2009;15(suppl 4):S81–S84.

14Nyholm D: Duodopa® treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism Relat Disord 2012;18:916–929.

15Munhoz RP, Cerasa A, Okun MS: Surgical treatment of dyskinesia in Parkinson’s disease. Front Neurol 2014;5:65.

16Louis ED: Essential tremor. Lancet Neurol 2005;4:100–110.

17Busenbark KL, Nash J, Nash S, Hubble JP, Koller WC: Is essential tremor benign? Neurology 1991;41:1982–1983.

18Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB Jr, Ondo WG, Gronseth GS, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology: Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005;64:2008–2020.

19Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB Jr, Okun MS, Sullivan KL, Weiner WJ: Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2011;77:1752–1755.

20Zappia M, Albanese A, Bruno E, Colosimo C, Filippini G, Martinelli P, Nicoletti A, Quattrocchi G, Abbruzzese G, Berardelli A, Allegra R, Aniello MS, Elia AE, Martino D, Murgia D, Picillo M, Squintani G: Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. J Neurol 2013;260:714–740. Erratum in: J Neurol 2013;260:741.

21Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK: Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013;28:863–873.

22Jankovic J: Medical treatment of dystonia. Mov Disord 2013;28:1001–1012.

23Bragg DG, Sharma N: Update on treatment of dystonia. Curr Neurol Neurosci Rep 2014;14:454.

24Balint B, Bhatia K: Dystonia: an update on phenomenology, classification, pathogenesis and treatment. Curr Opin Neurol 2014;27:468–476.

25Armstrong MJ, Miyasaki JM: Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American academy of neurology. Neurology 2012;79:597–603.

26Reilmann R: Pharmacological treatment of chorea in Huntington’s disease-good clinical practice versus evidence-based guideline. Mov Disord 2013;28:1030–1033.

Dr. Renato Puppi Munhoz, MD, PhD

Movement Disorders Centre Toronto Western

Hospital Division of Neurology, University of Toronto

399 Bathurst St., 7 Mc412

Toronto, ON Canada M5T 2S8 (USA)

E-Mail renato.munhoz@uhn.ca